|
1
|
Turesson I, Velez R, Kristinsson SY and
Landgren O: Patterns of improved survival in patients with multiple
myeloma in the twenty-first century: a population-based study. J
Clin Oncol. 28:830–834. 2010. View Article : Google Scholar :
|
|
2
|
Kumar SK, Rajkumar SV, Dispenzieri A, et
al: Improved survival in multiple myeloma and the impact of novel
therapies. Blood. 111:2516–2520. 2008. View Article : Google Scholar
|
|
3
|
Kristinsson SY, Landgren O, Dickman PW, et
al: Patterns of survival in multiple myeloma: a population-based
study of patients diagnosed in Sweden from 1973 to 2003. J Clin
Oncol. 25:1993–1999. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dunkley S, Gibson J, Iland H, Li C and
Joshua D: Acute promyelocytic leukaemia complicating multiple
myeloma: evidence of different cell lineages. Leuk Lymphoma.
35:623–626. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Morgan GJ, Davies FE, Gregory WM, et al:
Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with
bisphosphonate and thalidomide treatment. Clin Cancer Res.
19:6030–6038. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bergsagel DE, Bailey AJ, Langley GR, et
al: The chemotherapy on plasma-cell myeloma and the incidence of
acute leukemia. N Engl J Med. 301:743–748. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
[No Authors Listed]. Acute leukaemia and
other secondary neoplasms in patients treated with conventional
chemotherapy for multiple myeloma. Eur J Haematol. 65:123–127.
2000. View Article : Google Scholar
|
|
8
|
Dong C and Hemminki K: Second primary
neoplasms among 53,159 haematolymphoproliferative malignancy
patients in Sweden, 1958–1996: a search for common mechanisms. Br J
Cancer. 85:997–1005. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hasskarl J, Ihorst G, De Pasquale D, et
al: Association of multiple myeloma with different neoplasms:
systematic analysis in consecutive patients with myeloma. Leuk
Lymphoma. 52:247–259. 2011. View Article : Google Scholar
|
|
10
|
Barlogie B, Tricot G, Haessler J, et al:
Cytogenetically defined myelodysplasia after melphalan-based
autotransplantation for multiple myeloma linked to poor
hematopoietic stem-cell mobilization: the Arkansas experience in
more than 3,000 patients treated since 1989. Blood. 111:94–100.
2008. View Article : Google Scholar
|
|
11
|
Przepiorka D, Buadi F, McClune B, et al:
Myelodysplastic syndrome after autologous peripheral blood stem
cell transplantation for multiple myeloma. Bone Marrow Transplant.
40:759–764. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Govindarajan R, Jagannath S, Flick JT, et
al: Preceding standard therapy is the likely cause of MDS after
autotransplants for multiple myeloma. Br J Haematol. 95:349–353.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cuzick J, Erskine S, Edelman D and Galton
DA: A comparison of the incidence of the myelodysplastic syndrome
and acute myeloid leukaemia following melphalan and
cyclophosphamide treatment for myelomatosis. A report to the
Medical Research Council’s working party on leukaemia in adults. Br
J Cancer. 55:523–529. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Featherstone C, Delaney G, Jacob S and
Barton M: Estimating the optimal utilization rates of radiotherapy
for hematologic malignancies from a review of the evidence: part II
leukemia and myeloma. Cancer. 103:393–401. 2005. View Article : Google Scholar
|
|
15
|
Berrington de Gonzalez A, Curtis RE, Kry
SF, et al: Proportion of second cancers attributable to
radiotherapy treatment in adults: a cohort study in the US SEER
cancer registries. Lancet Oncol. 12:353–360. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Berrington de Gonzalez A, Curtis RE,
Gilbert E, et al: Second solid cancers after radiotherapy for
breast cancer in SEER cancer registries. Br J Cancer. 102:220–226.
2010. View Article : Google Scholar :
|
|
17
|
Attal M and Cances-Lauwers V: Maintenance
treatment with lenalidomide after transplantation for myeloma:
analysis of secondary malignancies within the IFM 2005-02 trial.
In: 13th International Myeloma Workshop; 2011, Paris, France
|
|
18
|
McCarthy P and Anderson K: Phase III
Intergroup study of lenalidomide versus placebo maintenance therapy
following single autologous stem cell transplant for multiple
myeloma CALGB ECOG BMT-CTN 100104. In: 13th International Myeloma
Workshop; 2011, Paris, France
|
|
19
|
Palumbo AP and Catalano J: Incidence of
second primary malignancy in melphalan-prednisone-lenalidomide
combination followed by lenalidomide maintenance in newly diagnosed
multiple myeloma patients age 65 or older [abstract]. J Clin Oncol.
29. 2011
|
|
20
|
Guthrie TH Jr: High-dose,
continuous-infusion cyclophosphamide, cytarabine, vincristine, and
prednisone for remission induction in refractory adult acute
leukemia. Cancer. 59:1255–1257. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nooka AK, Kaufman JL, Behera M, et al:
Bortezomib-containing induction regimens in transplant-eligible
myeloma patients: a meta-analysis of phase 3 randomized clinical
trials. Cancer. 119:4119–4128. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Richardson PG, Schlossman RL, Alsina M, et
al: PANORAMA 2: panobinostat in combination with bortezomib and
dexamethasone in patients with relapsed and bortezomib-refractory
myeloma. Blood. 122:2331–2337. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gay F, Hayman SR, Lacy MQ, et al:
Lenalidomide plus dexamethasone versus thalidomide plus
dexamethasone in newly diagnosed multiple myeloma: a comparative
analysis of 411 patients. Blood. 115:1343–1350. 2010. View Article : Google Scholar :
|
|
24
|
Dimopoulos MA, Delforge M, Hájek R, et al:
Lenalidomide, melphalan, and prednisone, followed by lenalidomide
maintenance, improves health-related quality of life in newly
diagnosed multiple myeloma patients aged 65 years or older: results
of a randomized phase III trial. Haematologica. 98:784–788. 2013.
View Article : Google Scholar :
|
|
25
|
Razavi P, Rand KA, Cozen W, et al:
Patterns of second primary malignancy risk in multiple myeloma
patients before and after the introduction of novel therapeutics.
Blood Cancer J. 28:e1212013. View Article : Google Scholar
|
|
26
|
Thomas A, Mailankody S, Korde N, et al:
Second malignancies after multiple myeloma: from 1960s to 2010s.
Blood. 119:2731–2737. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Greene MH, Harris EL, Gershenson DM, et
al: Melphalan may be a more potent leukemogen than
cyclophosphamide. Ann Intern Med. 105:360–367. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Usmani SZ, Sexton R, Hoering A, et al:
Second malignancies in total therapy 2 and 3 for newly diagnosed
multiple myeloma: influence of thalidomide and lenalidomide during
maintenance. Blood. 20:1597–1600. 2012. View Article : Google Scholar
|
